-transparent.png){kind=logo}
The effect of rigvir, an immunomodulator of the viral origin, on cell-mediated immunity was studied in patients with skin malignant melanoma. Rosette formation and monoclonal antibody techniques were used to measure blood immunocompetent cell levels in patients with the above pathology, cases of benign skin tumors and healthy subjects. Rigvir was shown to influence natural resistance by raising blood monocyte and large granule-containing lymphocyte levels. It potentiated recruitment of pre-T-lymphocytes and young active T-lymphocytes to the peripheral blood.
Related Publications
L S Glinkina, and
R Zh Bruvere, and
D R Venskus, and
R R Garklava, and
A J Muceniece
January 1992,
Voprosy onkologii,
L S Glinkina, and
R Zh Bruvere, and
D R Venskus, and
R R Garklava, and
A J Muceniece
January 1973,
Voprosy onkologii,
L S Glinkina, and
R Zh Bruvere, and
D R Venskus, and
R R Garklava, and
A J Muceniece
November 1973,
The British journal of surgery,
L S Glinkina, and
R Zh Bruvere, and
D R Venskus, and
R R Garklava, and
A J Muceniece
January 1991,
Wiener klinische Wochenschrift,
L S Glinkina, and
R Zh Bruvere, and
D R Venskus, and
R R Garklava, and
A J Muceniece
January 1976,
Voprosy onkologii,
L S Glinkina, and
R Zh Bruvere, and
D R Venskus, and
R R Garklava, and
A J Muceniece
July 1973,
British journal of cancer,
L S Glinkina, and
R Zh Bruvere, and
D R Venskus, and
R R Garklava, and
A J Muceniece
January 1987,
Meditsinskaia parazitologiia i parazitarnye bolezni,
L S Glinkina, and
R Zh Bruvere, and
D R Venskus, and
R R Garklava, and
A J Muceniece
August 1980,
Ceskoslovenska dermatologie,
L S Glinkina, and
R Zh Bruvere, and
D R Venskus, and
R R Garklava, and
A J Muceniece
January 2017,
Oncolytic virotherapy,
L S Glinkina, and
R Zh Bruvere, and
D R Venskus, and
R R Garklava, and
A J Muceniece
September 1971,
International journal of cancer,
